A Phase II, Open Label, Single-Center, Clinical Trial to Assess Safety and Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Hope Biosciences
Most Recent Events
- 26 May 2021 Status changed from active, no longer recruiting to completed.
- 23 Feb 2021 Planned End Date changed from 31 Dec 2020 to 1 May 2021.
- 21 Oct 2020 Status changed from recruiting to active, no longer recruiting.